US 11,744,884 B2
Live Salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
James E. Galen, Eldersburg, MD (US); Thanh Pham, Baltimore, MD (US); Dacie R. Bridge, Blairsville, PA (US); Jin Yuan Wang, Silver Spring, MD (US); and Wangxue Chen, Ottawa (CA)
Assigned to UNIVERSITY OF MARYLAND, BALTIMORE, Baltimore, MD (US); and NATIONAL RESEARCH COUNCIL OF CANADA, Ontario (CA)
Appl. No. 16/614,261
Filed by University of Maryland, Baltimore, MD (US); and National Research Council of Canada, Ottawa (CA)
PCT Filed May 15, 2018, PCT No. PCT/US2018/032662
§ 371(c)(1), (2) Date Nov. 15, 2019,
PCT Pub. No. WO2018/213242, PCT Pub. Date Nov. 22, 2018.
Claims priority of provisional application 62/506,078, filed on May 15, 2017.
Prior Publication US 2020/0179501 A1, Jun. 11, 2020
Int. Cl. A61K 39/02 (2006.01); A61K 39/05 (2006.01); A61K 39/112 (2006.01); A61K 39/108 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/0275 (2013.01) [A61K 39/0266 (2013.01); A61K 39/05 (2013.01); A61K 2039/523 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01)] 20 Claims
 
1. An immunogenic live Salmonella Typhi vector that has been engineered to express one or more heterologous antigens from a pathogen, wherein the heterologous antigen comprises outer membrane protein OmpW or an antigenic fragment or variant thereof and comprises outer membrane protein OmpA or an antigenic fragment or variant thereof, wherein the live Salmonella Typhi vector is capable of delivering immunogenic, recombinant outer membrane vesicles (rOMVs) to a mucosal tissue when administered to a subject, wherein the vesicles comprise the heterologous antigens, wherein the Salmonella Typhi vector has been engineered to overexpress a lipid A deacylase PagL.